Trials / Completed

CompletedNCT00001991

A Treatment IND for 566C80 Therapy of Pneumocystis Carinii Pneumonia

Status: Completed
Phase: N/A
Study type: Interventional
Enrollment: —

Sponsor: Glaxo Wellcome · Industry
Sex: All
Age: 1 Day
Healthy volunteers: Not accepted

Summary

To facilitate provision of atovaquone (566C80) to patients who have mild to moderate Pneumocystis carinii pneumonia (PCP) and are intolerant and/or unresponsive to trimethoprim / sulfamethoxazole (TMP / SMX ); to monitor serious adverse events attributable to 566C80.

Conditions

Pneumonia, Pneumocystis Carinii
HIV Infections

Interventions

Type	Name	Description
DRUG	Atovaquone

Timeline

First posted: 2001-08-31
Last updated: 2005-06-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00001991. Inclusion in this directory is not an endorsement.